IRCT20200623047902N38招募中Unknown
Bioequivalence study of Linagliptin/metformin 2.5/1000 mg tablet manufactured by Actover Co. versus originator brand in healthy volunteers in fasting condition
Actover Co.0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcoholism and Narcoticism
- •History of allergy to Linagliptin/metformin
研究者
相似试验
已完成
1 期
Bioequivalence of a Linagliptin / Metformin Fixed-dose Combination (FDC) Tablet Compared With Single Linagliptin and Metformin Tablets Administered Together in Healthy VolunteersHealthyNCT02221401Boehringer Ingelheim96
已完成
1 期
Bioequivalence of a 2.5 mg Linagliptin / 500 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 500 mg Tablets Administered Together in Healthy VolunteersHealthyNCT02221414Boehringer Ingelheim95
已完成
1 期
Bioequivalence of a 2.5 mg Linagliptin / 850 mg Metformin Fixed Dose Combination Tablet Compared With Single Linagliptin 2.5 mg and Metformin 850 mg Tablets in Healthy VolunteersHealthyNCT02220647Boehringer Ingelheim96
已完成
1 期
Bioequivalence of Metformin Under Fed Conditions After Administration of Linagliptin / Metformin Fixed Dose Combination Tablet and Single TabletsHealthyNCT01581931Boehringer Ingelheim32
尚未招募
Unknown
Bioequivalence Study of Linagliptin/Metformin 2.5/1000 mg FC. Tablets of The Test Drug (Kharazmi Pharma, Iran)IRCT20200105046010N101Kharazmi Pharmacy24